Compare stocks
Market: US
WSTWest Pharmaceutical Services
Add stock
Ticker or company
Summary

WST
West Pharmaceutical Services
$417,80Up +0,33%
Year: Up +56%
83/100★★★★★★★★★Ratio would consider buying
Open stock pageTraffic light — 10 checks
| Check | WST7 ✓ 1 — 1 ✕ |
|---|---|
| P/E vs its history | 45,5 |
| P/E vs industry | 45,5 |
| Forward P/E | 40,5 |
| Revenue growth, YoY | +12,6% |
| EPS growth, YoY | +32,0% |
| Net margin | 18,8% |
| Net debt / EBITDA | −0,3 |
| Free cash flow | $453 m |
| Share count over a year | −2,5% |
| Cash runway | n/anot needed |
Metrics
Best WorstNo mark — in between
| Metric · better | WSTTTM | Industry medianTTM |
|---|---|---|
| P/E TTM ↓ | 45,5 | 37,9 |
| Forward P/E ↓ | 40,5 | 29,5 |
| PEG ↓ | 2,6 | 3,7 |
| P/S TTM ↓ | 8,6 | 6,6 |
| EV/EBITDA ↓ | 30,0 | 29,9 |
| P/FCF ↓ | 64,2 | 38,7 |
Price, %
- WSTn/a
Returns
Best WorstNo mark — in between
| Period | WST |
|---|---|
| 1 year | n/a |
| 3 years | n/a |
| 5 years | n/a |
| All time | n/a |
“Per year” is the average annual return: 90% growth over 3 years is 23,9% per year, not 30%. “All time” starts at the IPO, so only “per year” compares fairly. Prices adjusted for splits, dividends reinvested.
Analysts and insiders
Best WorstNo mark — in between
| WST | |
|---|---|
| Share of “buy” | 95% |
| Beat the forecast | 4 of 4 |
| Average “surprise” | +17,2% |
| Insiders over 12 months | sales $6,57 m |
Details are on each stock page.